| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 299.7 | 286.6 |
| Gross profit | 196.6 | 188.1 |
| Profit before tax | 34.7 | 48.0 |
| Net income | 28.3 | 38.2 |
| EPS (diluted, $ a share) | $0.18 | $0.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -25.9% |
|---|---|
| Revenue, year on year | +4.6% |
| Gross margin | 65.6% |
| Operating margin | 12.2% |
10-Q filed with the SEC, NASDAQ: TECH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BIO-TECHNE Corp: key numbers
- Share price
- $72.79Close, Nov 16
- Market cap
- $11.4B
- Shares outstanding
- 157.06MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BIO-TECHNE Corp
All →BIO-TECHNE Dividend
Bio-Techne Corporation declared a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026. The dividend is payable on November 23, 2026, to shareholders of record as of November 13, 2026, contingent upon the company's pending acquisition by Merck KGaA not closing before the record date.
BIO-TECHNE M&A Deal with Merck KGaA, Darmstadt, Germany
Bio-Techne shareholders voted to approve the company's acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting held on September 23, 2026. The transaction has also cleared the HSR Act antitrust waiting period and is expected to close by late 2026 or early 2027. Bio-Techne will become a wholly-owned subsidiary of Merck KGaA upon completion of the merger.
- Counterparty
- Merck KGaA, Darmstadt, Germany
BIO-TECHNE M&A Deal with Merck KGaA, Darmstadt, Germany
Bio-Techne Corporation provided a status update on its pending merger with Merck KGaA, Darmstadt, Germany, specifically addressing shareholder litigation and demand letters alleging disclosure deficiencies in the proxy statement. To avoid potential delays to the merger and the scheduled September 23, 2026 shareholder vote, the company has voluntarily issued supplemental disclosures while maintaining that the legal claims are without merit.
- Counterparty
- Merck KGaA, Darmstadt, Germany